Trans youth will no longer be prescribed puberty blockers at NHS England gender identity clinics in a new “blow” to gender-affirming healthcare.
Puberty blockers are a type of medicine that prevent puberty from starting by blocking the hormones – like testosterone and oestrogen – that lead to puberty-related changes in the body. In the case of trans youth, this can delay unwanted physical changes like menstruation, breast growth, voice changes or facial hair growth.
On Tuesday (12 March), NHS England confirmed the medicine, which has been described as “life-saving” medical care for trans youth, will only be available to young people as part of clinical research trials.
The government described the move as a “landmark decision”, Sky News reported. It believed such a move is in the “best interests of the child”.
Yes, there are side effects. They vary depending on the length of treatment (generally patients are not allowed to stay on them indefinitely to mitigate this) and the medication used, but puberty blockers have been used for ~40 years now and we have a good understanding of the risks. GnRH agonists are the most common type of puberty blocker used today, and the typical side effects are:
These side effects generally end once treatment stops, whether switching to hormone replacement therapy or stopping all gender-affirming treatment. These side effects are typical of low sex hormone levels in general, and are generally annoyances that can be managed rather than major risks that are likely to harm the patient long term. It’s also worth noting that some of these are seen as neutral or even positive to some patients - e.g. patients who were assigned male at birth and are interested in feminizing treatment often consider gynecomastia and decreased erectile function as positive effects.
When puberty blockers are continued for longer periods of time, there are additional risks which grow with the duration of the treatment:
These risks are more serious, which is why puberty blockers are not prescribed indefinitely. For gender affirming treatment, puberty blockers are generally prescribed for up to two or three years, depending on local regulations and the patient’s tolerance of the treatment. After this period, patients have the option of either continuing gender affirming treatment with hormone replacement therapy (so that they can experience a different puberty than the one typically associated with their birth sex), or stopping treatment and allowing puberty to run its course as usual.
It’s also worth noting that puberty blockers are not considered in a vacuum - the risks are considered against the risk of allowing puberty to continue as usual. For children with gender dysphoria, puberty is often a severely traumatic experience. This can cause or worsen depression and suicidality, and can leave a transgender person with sexual characteristics they do not want and will have to treat later with riskier and/or more intense forms of treatment like surgery. The risks of puberty blockers are comparatively mild, which is part of why the side effects are regarded as safe for transgender patients.
Lastly, I’ll also note that all of this treatment involves mental health professionals as well. While adults in some regions can choose to start gender affirming treatment on their own without needing a formal diagnosis, treatment for children requires much more work and dedication. Typically, a minor who wants to begin gender affirming treatment for gender dysphoria will need: